Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monthly recombinant factor XIII replacement in congenital factor XIII deficiency
2008-007883-41Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of catridecacog in congenital factor XIII deficiency and hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Adverse events (serious and non-serious). Started Jun 2009; status: completed.
02
Drugs
catridecacog
03
Conditions
congenital factor XIII deficiencyhemophilia A
Beyond the preview
Go deeper on 2008-007883-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007883-41.